Acquisition Impact EndoChoice was acquired by Boston Scientific in 2016 for about $210 million, indicating a legacy technology and product portfolio that may still be embedded in a broader sales ecosystem. Target follow-on deals and cross-sell opportunities with Boston Scientific’s networks and partners to expand reach in gastroenterology imaging, infection control, and pathology services.

Global Reach While primarily U.S.-focused with over 2,500 customers, EndoChoice engages distribution partners in 25 countries. Leverage international channels to introduce Full Spectrum Endoscopy and infection control devices to new markets, especially where GI screening adoption is rising.

Portfolio Synergy The company has a broad portfolio spanning endoscopic imaging systems, infection control products, and pathology services, presenting cross-sell opportunities to hospitals and GI centers seeking integrated solutions from a single vendor.

Decision Makers Direct sales organization suggests access to procurement and clinical decision-makers within gastroenterology practices and hospital systems. Focus on value-based demonstrations, ROI on early cancer detection, and infection control improvements to open pilot programs.

Growth Opportunity Revenue range and substantial funding indicate growth potential in mid-market and emerging markets. Propose scalable service contracts, training, and implementation support for new geographies and partner networks to accelerate adoption of their Full Spectrum Endoscopy System and related devices.